Bionano Genomics Q3 2023 Adj EPS $(1.01) Misses $(0.94) Estimate, Sales $9.32M Beat $8.98M Estimate
Portfolio Pulse from saritha@benzinga.com
Bionano Genomics reported Q3 2023 losses of $(1.01) per share, missing the analyst consensus estimate of $(0.94) by 7.45%. However, the company's quarterly sales of $9.32 million beat the estimate of $8.98 million by 3.76%, marking a 29.04% increase from the same period last year.
November 08, 2023 | 9:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bionano Genomics' Q3 2023 earnings missed estimates, but sales exceeded expectations and showed significant YoY growth.
While Bionano Genomics missed earnings estimates, which could negatively impact the stock, the company beat sales estimates and showed strong YoY growth, which could have a positive effect. The net impact is likely to be neutral in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100